Showing results (81-90 of 93) with videos related to
Sort By:
Pageof 10
Lancet (London, England)|April 7, 2012
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trialAndreas Engert, Heinz Haverkamp, Carsten Kobe, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2002
Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphomaUlrich Kaiser, Irmgard Uebelacker, Ulrich Abel, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2013
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IVRüdiger Hehlmann, Martin C Müller, Michael Lauseker, et al.Blood|November 1, 2011
Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IVAlice Fabarius, Armin Leitner, Andreas Hochhaus, et al.Blood|March 22, 2014
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trialStephan Stilgenbauer, Andrea Schnaiter, Peter Paschka, et al.Nature|October 16, 2015
Mutations driving CLL and their evolution in progression and relapseDan A Landau, Eugen Tausch, Amaro N Taylor-Weiner, et al.Blood|October 5, 2018
IG-MYC + neoplasms with precursor B-cell phenotype are molecularly distinct from Burkitt lymphomasRabea Wagener, Cristina López, Kortine Kleinheinz, et al.Lancet (London, England)|June 18, 2016
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma NetworkOlivier Hermine, Eva Hoster, Jan Walewski, et al.Annals of Hematology|September 20, 2015
Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CMLAlice Fabarius, Lida Kalmanti, Christian T Dietz, et al.Lancet (London, England)|December 24, 2019
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trialViola Poeschel, Gerhard Held, Marita Ziepert, et al.Pageof 10